{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T02:47:34Z","timestamp":1648694854747},"reference-count":42,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,1,17]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p>Background: Direct-acting Antivirals (DAA) are currently used in the treatment of chronic\nHCV infection. In patients with renal failure Glecaprevir\/Pibrentasvir (genotype 1-6) is recommended\nfor its safety and efficacy.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Case Presentation: <\/jats:title>\n<jats:p>Although these pharmacological characteristics, an adverse drug reaction (ADR)\nhas been reported during Glecaprevir\/Pibrentasvir treatment, such as the development of cholestatic\njaundice in an elderly patient with chronic HCV (genotype 2) infection. At examination, patient was\njaundiced associated with intense pruritus.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results: <\/jats:title>\n<jats:p>Ultrasound and laboratory biochemical tests excluded a liver failure (e.g. liver cancer, and\nliver lithiasis) or pancreatic cancer while Naranjo probability scale (score 6) suggested an association\nbetween cholestatic jaundice and Glecaprevir\/Pibrentasvir administration. About 1 month after drug\ndiscontinuation, an improvement has been documented in both jaundice and pruritus, with a\nnormalization in bilirubin levels (total bilirubin: 0.96 mg\/dL), HCV-RNA was undetected also. It is\nworth mentioning that although we reported the development of cholestatic jaundice upon treatment\nwith Glecaprevir\/Pibrentasvir we recorded a clinical efficacy (HCV-RNA &lt;15 IU\/L) after 4 weeks\nfrom the beginning of the treatment, with a complete remission of clinical symptoms until 7 months\nafter drug discontinuation.\n<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion: <\/jats:title>\n<jats:p>These data support the clinical efficacy of Glecaprevir\/Pibrentasvir association in elderly\npatients, despite the sub-optimal period of treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886313666181116100452","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T11:02:29Z","timestamp":1542366149000},"page":"67-71","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glecaprevir\/Pibrentasvir Induced Cholestatic Jaundice in a HCV Patient with Renal Failure. A Case Presentation"],"prefix":"10.2174","volume":"14","author":[{"given":"Benedetto","family":"Caroleo","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Caroleo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Health and Nutritional Sciences, University of Calabria, Rende (CS), Calabria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cimellaro","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Colangelo","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Perticone","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science, Elderly Operative Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Di Mizio","sequence":"additional","affiliation":[{"name":"Department of Law and Economic Science, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Clinical Pharmacology and Pharmacovigilance Unit, Mater Domini Hospital, University of Catanzaro, Catanzaro, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1756284818759483","DOI":"10.1177\/1756284818759483","volume":"11","author":"Crouchet E.","year":"2018","unstructured":"Crouchet E, Wrensch F, Schuster C, Zeisel MB, Baumert TF.  Host-targeting therapies for hepatitis C virus infection: Current developments and future applications.","journal-title":"Therap Adv Gastroenterol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"Liang T.J.","year":"2013","unstructured":"Liang TJ, Ghany MG.  Current and future therapies for hepatitis C virus infection.","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"Sherman K.E.","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH.  Response-guided telaprevir combination treatment for hepatitis C virus infection.","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"Poordad F.","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR.  Boceprevir for untreated chronic HCV genotype 1 infection.","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10620-014-3374-1","volume":"60","author":"Dubin P.H.","year":"2015","unstructured":"Dubin PH, Sclair SN, Rico R.  Low SVR rates in clinical practice for treating genotype 1 chronic hepatitis C with protease inhibitors boceprevir and telaprevir.","journal-title":"Dig Dis Sci"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"Bourliere M.","year":"2017","unstructured":"Bourliere M, Gordon SC, Flamm SL.  Sofosbuvir, Velpatasvir, and Voxilaprevir for previously treated HCV infection.","journal-title":"N Engl J Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(18)30118-3","volume":"3","author":"Bourliere M.","year":"2018","unstructured":"Bourliere M, Gordon SC, Schiff ER.  Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: An open-label substudy of POLARIS-1.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref=8","first-page":"pii: e02558","volume":"61","author":"Ng T.I.","year":"2017","unstructured":"Ng TI, Krishnan P, Pilot-Matias T.  \n                         antiviral activity and resistance profile of the Next-Generation hepatitis C virus ns5a inhibitor pibrentasvir.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=9","first-page":"pii: e01620","volume":"62","author":"Ng T.I.","year":"2018","unstructured":"Ng TI, Tripathi R, Reisch T.  \n                         antiviral activity and resistance profile of the Next-Generation Hepatitis C virus ns3\/4a protease inhibitor glecaprevir.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.29081","volume":"66","author":"Poordad F.","year":"2017","unstructured":"Poordad F, Felizarta F, Asatryan A.  Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.","journal-title":"Hepatology"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","volume":"67","author":"Poordad F.","year":"2018","unstructured":"Poordad F, Pol S, Asatryan A.  Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.","journal-title":"Hepatology"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"Puoti M.","year":"2018","unstructured":"Puoti M, Foster GR, Wang S.  High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.","journal-title":"J Hepatol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000205266","volume":"51","author":"Caroleo B.","year":"2008","unstructured":"Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V.  Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.","journal-title":"Intervirology"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/157488609789006912","volume":"4","author":"Gallelli L.","year":"2009","unstructured":"Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M.  Hepatotoxicity induced by methimazole in a previously healthy patient.","journal-title":"Curr Drug Saf"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1055\/s-2006-946707","volume":"39","author":"Gallelli L.","year":"2006","unstructured":"Gallelli L, De Fazio S, Corace E, De Sarro G, Garcia CS, De Fazio P.  Generalised urticaria in a young woman treated with clomipramine and after ingestion of codfish.","journal-title":"Pharmacopsychiatry"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"Naranjo C.A.","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM.  A method for estimating the probability of adverse drug reactions.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/00044011-200727020-00004","volume":"27","author":"Gallelli L.","year":"2007","unstructured":"Gallelli L, Colosimo M, Pirritano D.  Retrospective evaluation of adverse drug reactions induced by nonsteroidal anti-inflammatory drugs.","journal-title":"Clin Drug Investig"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1043-6618(03)00003-3","volume":"47","author":"Gallelli L.","year":"2003","unstructured":"Gallelli L, Ferreri G, Colosimo M.  Retrospective analysis of adverse drug reactions to bronchodilators observed in two pulmonary divisions of Catanzaro, Italy.","journal-title":"Pharmacol Res"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17474124.2018.1411802","volume":"12","author":"Hubbard H.","year":"2018","unstructured":"Hubbard H, Lawitz E.  Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14656566.2018.1444030","volume":"19","author":"Carrion A.F.","year":"2018","unstructured":"Carrion AF, Martin P.  Glecaprevir + pibrentasvir for treatment of hepatitis C.","journal-title":"Expert Opin Pharmacother"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12072-018-9873-y","volume":"12","author":"Abutaleb A.","year":"2018","unstructured":"Abutaleb A, Kottilil S, Wilson E.  Glecaprevir\/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.","journal-title":"Hepatol Int"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"Asselah T.","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N.  Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref=23","first-page":"S528","volume":"66","author":"Toyoda H.","year":"2017","unstructured":"Toyoda H, Chayama K, Suzuki F.  Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.","journal-title":"Hepatology"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","volume":"68","author":"Reau N.","year":"2018","unstructured":"Reau N, Kwo PY, Rhee S.  Glecaprevir\/Pibrentasvir Treatment in Liver or kidney transplant patients with hepatitis C virus infection.","journal-title":"Hepatology"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"Kumada H.","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F.  Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.","journal-title":"J Gastroenterol"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13027-017-0119-8","volume":"12","author":"Nappi A.","year":"2017","unstructured":"Nappi A, Perrella A, Bellopede P.  Safety of new DAAs for chronic HCV infection in a real life experience: Role of a surveillance network based on clinician and hospital pharmacist.","journal-title":"Infect Agent Cancer"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1053\/j.gastro.2012.02.013","volume":"142","author":"Barritt A.St.","year":"2012","unstructured":"Barritt ASt, Fried MW.  Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.","journal-title":"Gastroenterology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"pii: bcr2015209586","DOI":"10.1136\/bcr-2015-209586","volume":"2015","author":"Caroleo B.","year":"2015","unstructured":"Caroleo B, Staltari O, Gallelli L, Perticone F.  Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: Drug interactions or low adherence?","journal-title":"BMJ Case Rep"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10517-012-1854-x","volume":"153","author":"Postnikova O.A.","year":"2012","unstructured":"Postnikova OA, Nepomnyashchikh GI, Yudanov AV, Nepomnyashchikh DL, Kapustina VI, Isayenko VI.  Intracellular cholestasis in HCV and HBV infection.","journal-title":"Bull Exp Biol Med"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"","year":"2017","unstructured":".  Clinical Practice Guidelines on the management of hepatitis B virus infection.","journal-title":"J Hepatol"},{"key":"ref=31","author":"","year":"","unstructured":".  US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. [Accessed August 10, 2017]."},{"key":"ref=32","author":"","year":"2018","unstructured":".  American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Available from:"},{"key":"ref=33","first-page":"536","volume":"13","author":"Pockros P.J.","year":"2017","unstructured":"Pockros PJ.  Black box warning for possible HBV reactivation during DAA therapy for chronic HCV infection.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3748\/wjg.v5.i3.252","volume":"5","author":"Assy N.","year":"1999","unstructured":"Assy N, Jacob G, Spira G, Edoute Y.  Diagnostic approach to patients with cholestatic jaundice.","journal-title":"World J Gastroenterol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.fct.2018.07.017","volume":"120","author":"Fernandez-Murga M.L.","year":"2018","unstructured":"Fernandez-Murga ML, Petrov PD, Conde I, Castell JV, Gomez-Lechon MJ, Jover R.  Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems.","journal-title":"Food Chem Toxicol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"808","DOI":"10.2174\/1389200219666180427165035","volume":"19","author":"Chatterjee S.","year":"2018","unstructured":"Chatterjee S, Annaert P.  Drug-induced cholestasis: Mechanisms, models, and markers.","journal-title":"Curr Drug Metab"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1111\/j.1572-0241.1998.00559.x","volume":"93","author":"Mergener K.","year":"1998","unstructured":"Mergener K, Enns R, Eubanks WS, Baillie J, Branch MS.  Pseudo-Mirizzi syndrome in acute cholecystitis.","journal-title":"Am J Gastroenterol"},{"key":"ref=38","first-page":"23","volume":"159","author":"Pasanen P.A.","year":"1993","unstructured":"Pasanen PA, Partanen KP, Pikkarainen PH, Alhava EM, Janatuinen EK, Pirinen AE.  A comparison of ultrasound, computed tomography and endoscopic retrograde cholangiopancreatography in the differential diagnosis of benign and malignant jaundice and cholestasis.","journal-title":"Eur J Surg"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001574-199705000-00002","volume":"13","author":"Crawford J.M.","year":"1997","unstructured":"Crawford JM.  Cellular and molecular biology of the inflamed liver.","journal-title":"Curr Opin Gastroenterol"},{"key":"ref=40","first-page":"6197152","volume":"2018","author":"Chan K.M.","year":"2018","unstructured":"Chan KM, Cheng CH, Wu TH.  De Novo Endotoxin-Induced production of antibodies against the bile salt export pump associated with bacterial infection following major hepatectomy.","journal-title":"BioMed Res Int"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1042\/bst0230993","volume":"23","author":"Spitzer J.A.","year":"1995","unstructured":"Spitzer JA, Zhang P.  Hepatic cellular interactions in endotoxaemia and sepsis.","journal-title":"Biochem Soc Trans"},{"key":"ref=42","first-page":"90","volume":"58","author":"Uhl B.","year":"1992","unstructured":"Uhl B, Speth V, Wolf B, Jung G, Bessler WG, Hauschildt S.  Rapid alterations in the plasma membrane structure of macrophages stimulated with bacterial lipopeptides.","journal-title":"Eur J Cell Biol"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T18:59:02Z","timestamp":1555873142000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167424\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886313666181116100452","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}